EMA goes one step forward about biosimilars

October 4, 2011 11:13 AM

European Medicines Agency (EMA) goes one step forward about biosimilars and invites feedback on plans to revise existing guidelines on biosimilar medicines.

As well known, Europe has the most regulated biosimilars market in the world. Europe’s regulatory watchdog, EMA (formerly EMEA) has published guidelines and approved several biosimilars till today. Additionally, EMA has also completed their preparations about biosimilar monoclonal antibodies guideline which will soon be published.

Now, the European Medicines Agency published a concept paper to start the three-month consultation period about the revision of the guideline of biosimilars. The deadline for comments is the last day of 2011 and the revised guideline will be published during the year 2012.

If you want to have look at the concept paper which asks for advice about clinical and non-clinical issues, you can click the link below:

Concept paper on the revision of the guideline on similar biological medicinal products

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!